Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - RELMADA THERAPEUTICS, INC. | f8k081718_relmada.htm |
Exhibit 16.1
United States Securities and Exchange Commission
Office of the Chief Accountant
100 F Street, N.E.
Washington, D.C. 20549
Ladies and Gentleman:
We have read the statements under Item 4.01 in the Form 8-K dated August 17, 2018, of Relmada Therapeutics, Inc. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm. We have no basis to agree or disagree with the other statements made by the Company in the Form 8-K.
Sincerely,
GBH CPAs, PC
www.gbhcpas.com
Houston, Texas
August 17, 2018